IX Biopharma Ltd
SGX:42C
Intrinsic Value
iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. [ Read More ]
The intrinsic value of one 42C stock under the Base Case scenario is 0.275 SGD. Compared to the current market price of 0.042 SGD, IX Biopharma Ltd is Undervalued by 85%.
Valuation Backtest
IX Biopharma Ltd
Run backtest to discover the historical profit from buying and selling 42C stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
IX Biopharma Ltd
Current Assets | 9.8m |
Cash & Short-Term Investments | 6.1m |
Receivables | 2.4m |
Other Current Assets | 1.3m |
Non-Current Assets | 8.5m |
Long-Term Investments | 88k |
PP&E | 8m |
Intangibles | 302k |
Other Non-Current Assets | 187k |
Current Liabilities | 7.1m |
Accounts Payable | 3.1m |
Other Current Liabilities | 3.9m |
Non-Current Liabilities | 3.6m |
Long-Term Debt | 2.9m |
Other Non-Current Liabilities | 666k |
Earnings Waterfall
IX Biopharma Ltd
Revenue
|
6.1m
SGD
|
Cost of Revenue
|
-4m
SGD
|
Gross Profit
|
2m
SGD
|
Operating Expenses
|
-8.6m
SGD
|
Operating Income
|
-6.6m
SGD
|
Other Expenses
|
-3m
SGD
|
Net Income
|
-9.6m
SGD
|
Free Cash Flow Analysis
IX Biopharma Ltd
42C Profitability Score
Profitability Due Diligence
IX Biopharma Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
IX Biopharma Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
42C Solvency Score
Solvency Due Diligence
IX Biopharma Ltd's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
IX Biopharma Ltd's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
42C Price Targets Summary
IX Biopharma Ltd
According to Wall Street analysts, the average 1-year price target for 42C is 0.25 SGD .
Shareholder Return
42C Price
IX Biopharma Ltd
Average Annual Return | -10.51% |
Standard Deviation of Annual Returns | 21.04% |
Max Drawdown | -100% |
Market Capitalization | 32.3m SGD |
Shares Outstanding | 768 317 356 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. The company developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The firm operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The firm's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.
Contact
IPO
Employees
Officers
The intrinsic value of one 42C stock under the Base Case scenario is 0.275 SGD.
Compared to the current market price of 0.042 SGD, IX Biopharma Ltd is Undervalued by 85%.